Drug Interactions between clonidine and Myfortic
This report displays the potential drug interactions for the following 2 drugs:
- clonidine
- Myfortic (mycophenolic acid)
Interactions between your drugs
No interactions were found between clonidine and Myfortic. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
clonidine
A total of 375 drugs are known to interact with clonidine.
- Clonidine is in the drug class antiadrenergic agents, centrally acting.
-
Clonidine is used to treat the following conditions:
- ADHD
- Alcohol Withdrawal (off-label)
- Anxiety (off-label)
- Atrial Fibrillation (off-label)
- Benzodiazepine Withdrawal (off-label)
- Bipolar Disorder (off-label)
- High Blood Pressure
- Hyperhidrosis (off-label)
- Hypertensive Emergency (off-label)
- Insomnia, Stimulant-Associated (off-label)
- Migraine Prevention (off-label)
- Opiate Withdrawal (off-label)
- Pain
- Perimenopausal Symptoms (off-label)
- Pheochromocytoma Diagnosis (off-label)
- Postanesthetic Shivering (off-label)
- Postherpetic Neuralgia (off-label)
- Postural Orthostatic Tachycardia Syndrome (off-label)
- Restless Legs Syndrome (off-label)
- Smoking Cessation (off-label)
- Tardive Dyskinesia (off-label)
- Tourette's Syndrome (off-label)
- Ulcerative Colitis (off-label)
Myfortic
A total of 339 drugs are known to interact with Myfortic.
- Myfortic is in the drug class selective immunosuppressants.
-
Myfortic is used to treat the following conditions:
- Dermatomyositis (off-label)
- Rejection Prophylaxis
Drug and food interactions
mycophenolic acid food
Applies to: Myfortic (mycophenolic acid)
ADJUST DOSING INTERVAL: Administration of enteric coated mycophenolic acid with meals may alter its pharmacokinetics relative to administration in the fasting state. When mycophenolic acid 720 mg was administered with a high-fat meal, there was a 33% decrease in the peak plasma concentration (Cmax); a 3.5-hour increase in delay time for the rise of plasma mycophenolic acid; and a 5-hour delay in the time to reach peak plasma concentration (Tmax). However, no effect was observed on the systemic exposure of mycophenolic acid.
MANAGEMENT: To avoid variability in drug absorption between doses, enteric coated formulations of mycophenolic acid should be taken on an empty stomach, one hour before or two hours after food intake. The tablets should be swallowed whole and not crushed, chewed or divided in order to maintain the integrity of the enteric coating.
References (1)
- (2004) "Product Information. Myfortic (mycophenolic acid)." Novartis Pharmaceuticals
cloNIDine food
Applies to: clonidine
MONITOR: Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.
MANAGEMENT: Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.
References (10)
- Sternbach H (1991) "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol, 11, p. 390-1
- Shook TL, Kirshenbaum JM, Hundley RF, Shorey JM, Lamas GA (1984) "Ethanol intoxication complicating intravenous nitroglycerin therapy." Ann Intern Med, 101, p. 498-9
- Feder R (1991) "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry, 52, p. 139
- Ellison JM, Milofsky JE, Ely E (1990) "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry, 51, p. 385-6
- Rodriguez de la Torre B, Dreher J, Malevany I, et al. (2001) "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit, 23, p. 435-40
- Cerner Multum, Inc. "Australian Product Information."
- Pacher P, Kecskemeti V (2004) "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des, 10, p. 2463-75
- Andrews C, Pinner G (1998) "Postural hypotension induced by paroxetine." BMJ, 316, p. 595
- (2023) "Product Information. Buprenorphine (buprenorphine)." G.L. Pharma UK Ltd
- (2023) "Product Information. Temgesic (buprenorphine)." Reckitt Benckiser Pty Ltd
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.